Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints
Non-alcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and a disease with high unmet medical need. Platform trials provide great benefits for sponsors and trial participants in terms of accelerating drug development programs. In this article, we describe some of the activities of the EU-PEARL consortium (EU Patient-cEntric clinicAl tRial pLatforms) regarding the use of platform trials in NASH, in particular the proposed trial design, decision rules and simulation results. For a set of assumptions, we present the results of a simulation study recently discussed with two health authorities and the learnings from these meetings from a trial design perspective. Since the proposed design uses co-primary binary endpoints, we furthermore discuss the different options and practical considerations for simulating correlated binary endpoints.
Fibrosis; Drug research and development; Decision making
Meyer EL, Mesenbrink P, Di Prospero NA, Pericàs JM, Glimm E, Ratziu V, et al. Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints. PLoS One. 2023 Mar 9;18(3):e0281674.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/9221
The following license files are associated with this item: